Oxfendazole
Article
Oxfendazole is a recurring brand in the Astral Codex Ten archive, appearing 3 times across 3 issues between November 04, 2022 and June 18, 2025. The archive places it in contexts such as “Develop Oxfendazole As A New Deworming Medication”; “Development of oxfendazole, a drug for treating parasitic worms”; “Antiparasitic medication oxfendazole continues to advance”. It most often appears alongside Manifold Markets, 1DaySooner, acanthamoeba keratitis.
Metadata
- Category: Brands
- Mention count: 3
- Issue count: 3
- First seen: November 04, 2022
- Last seen: June 18, 2025
Appears In
Related Pages
-
- Manifold Markets (3 shared issues)
-
- 1DaySooner (2 shared issues)
-
- acanthamoeba keratitis (2 shared issues)
-
- ACX (2 shared issues)
-
- ACX (2 shared issues)
-
- ACX Grants (2 shared issues)
-
- ACX Grants (2 shared issues)
-
- African Swine Fever (2 shared issues)
-
- AI Safety (2 shared issues)
-
- Alice Evans (2 shared issues)
-
- ALLFED (2 shared issues)
-
- Australia (2 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
11: Develop Oxfendazole As A New Deworming Medication (10/10) The Oxfendazole Development Group has received a further $1.6 million from Open Philanthropy. They have completed several studies on metabolites and drug interactions, and are working on more. It is still early in the approval process but they are optimistic. They are looking for further funding to better characterize the physical/chemical properties of oxfendazole; contact here if you are able to help.
Inline links: here
Oxfendazole Development Group is looking for more funding; contact them here if interested.
Inline links: here
Development of oxfendazole, a drug for treating parasitic worms in developing countries.
11: Develop Oxfendazole As A New Deworming Medication
Drug development is a highly regulated process; it is not glitzy. But this necessary path to bring a new medicine to deworming efforts world-wide is no the less important because of having to follow a prescribed pathway. To this end and because of the largesse of donors, we have completed several nonclinical studies on oxfendazole itself, on its physical chemical properties, and on its potential for toxicity in a rodent and a non-rodent species.
These studies support our clinical work, following successful completion of two Phase I studies. We are presently collaborators on three Phase II efficacy studies taking place in Peru on three different parasitic diseases, an approach to ascertain the range (in terms of disease and dose) of oxfendazole’s efficacy.